<DOC>
	<DOCNO>NCT00833352</DOCNO>
	<brief_summary>This prospective , randomize , single blind , multi-centre study examine effect right ventricular ( RV ) lead location patient implanted cardiac resynchronization defibrillator . 1 . Purpose : To compare effect RV mid-septal ( RVS ) versus RV apical ( RVA ) lead location leave ventricular reverse remodel patient indicated cardiac resynchronization therapy device ( CRT-D ) period 6 month evaluate clinical outcome RVS versus RVA pacing , period 12 month . 2 . Objectives : The primary objective demonstrate difference two group ( RVA vs. RVS ) change leave ventricular end systolic volume ( LVESV ) , baseline 6 month . The secondary objective evaluate percentage `` echo-responders '' plus additional clinical safety outcomes . This prospective , randomize , multi-centre , single-blind 2 parallel arm , non-inferiority study conduct approximately 25 study centre Europe . The patient randomize 1:1 ratio . A maximum 416 patient enrol study . All eligible patient follow baseline , randomisation , pre discharge , 1 , 6 12 month post-implant . Enrolment expect complete 18 month . The total duration study expect approximately 30 month .</brief_summary>
	<brief_title>Comparison Right Ventricular Septal Right Ventricular Apical Pacing Patients Receiving CRT-D Device</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<mesh_term>Ventricular Fibrillation</mesh_term>
	<criteria>Accepted CRT indication accord ESC 1 . Documented LVEF &lt; /= 35 % last 3 month 2 . Documented LVEDD ≥ 55 mm LVEDD &gt; 30 mm/m2 , LVEDD &gt; 30 mm/m ( height ) last 3 month 3 . QRS ≥120 m document ECG record hospitalisation 4 . NYHA Class III ambulatory class IV stable last month previous enrolment Or previous criterion 1 2 transient episode NYHA class III IV prior HF hospitalization intravenous decongestive therapy ( IV diuretic , IV neseritide IV inotropes ) `` outpatient '' set within year previous enrolment stabilization NYHA class II last month QRS ≥150 m document ECG record hospitalisation ICD indication ( class I II A ) Optimal stable medication least one month ( except diuretic stable minimum 1 week ) base ESC guideline enrolment Chronic heart failure ( &gt; 3 month ) stable last month previous enrolment Stable sinus rhythm enrolment Willing capable providing inform consent Exclusion Criteria Defibrillation test plan implant procedure due poor haemodynamic clinical status reason Have persistent atrial fibrillation ( AF ) atrial flutter ( i.e , terminate medical intervention , terminate spontaneously ) within 1 month prior inclusion Documented AF within 1 month prior enrolment Life expectancy &lt; 12 month expect undergo heart transplant within next 12 month Uncontrolled blood pressure ( Systolic BP &gt; 160 mmHg Diastolic BP &gt; 85 mmHg ) Hospitalization HF intravenous inotropic drug treatment within 1 month prior enrolment Cardiac surgery , per cutaneous transluminal angioplasty ( PTCA ) , myocardial infarction ( MI ) , unstable severe angina stroke last 3 month prior enrolment Previously implant pacemaker ICD Uncorrected primary valvular disease Prosthetic tricuspid valve Nursing woman childbearing potential , might pregnant time study Enrolled ongoing study ( include pharmacologic trial ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>